Zurich-based biotech company Mabylon AG has successfully secured CHF 30 million, equivalent to around €32 million, from existing private investors. This funding consists of equity investment and convertible loans, with significant contributions from former Roche management and board members. Through this financial boost, Mabylon aims to push forward its research in antibody therapeutics, with promising potential in the fields of allergy, inflammation, and neurology. By leveraging this backing, the biotech firm seeks to bring innovative and effective solutions to these pressing health concerns.
The recent funding initiative aligns with Mabylon’s history of innovative strides in medicine. In earlier phases, the company has set ambitious goals to revolutionize allergy and neurology treatments through human-derived antibodies. Mabylon’s previous achievements laid a foundation that enabled the company to attract attention from prominent investors and stakeholders, particularly those affiliated with established industry giant Roche. This funding solidifies Mabylon’s trajectory towards achieving its research objectives.
What is Mabylon’s Main Objective?
The newly acquired funds will primarily support Mabylon’s lead program, MY006, which focuses on creating a tri-specific antibody designed to neutralize peanut allergens. The company plans to bring MY006 through to the completion of a Phase Ia/b clinical trial by 2027. Additionally, Mabylon is working on MY010 and MY011, each targeting various allergens such as the birch Bet v 1 allergen and grass pollen allergies. By expanding its research and discovery programs, the biotech company commits to addressing diversified allergenic challenges.
What Are the Leadership Changes at Mabylon?
Mabylon also announced the election of Dr. Thomas Hecht as a new board member, replacing Prof. Adriano Aguzzi, whose term concluded in June 2025. Dr. Hecht’s extensive industry experience is expected to facilitate the growth and commercial success of Mabylon’s allergen-neutralizing solutions. This change in leadership is perceived as a strategic move to usher in a fresh perspective and added expertise to the company. Additionally, Dr. Hecht’s guidance is anticipated to be instrumental in navigating the complex biotechnology landscape.
CEO Alcide Barberis underscored the importance of the funding during a trying global economic period and expressed optimism regarding the company’s strategic direction, stating,
“We are very pleased to have closed a CHF 30 million financing agreement in such a challenging global funding environment.”
His remarks reflect the company’s resilience and adaptability to market conditions, ensuring that research initiatives remain unaffected by broader financial challenges.
Chairman Gottlieb Keller shared insights into how the funds will fuel Mabylon’s innovation pipeline:
“MY006 is a multi-specific anti-allergen antibody for the prophylactic treatment of peanut allergy, an indication with a high unmet medical need.”
His statement highlights the company’s commitment to addressing pressing health needs through state-of-the-art biotechnology developments.
Mabylon’s focus remains on utilizing human-derived antibodies, which offer greater efficacy compared to those sourced from traditional methods like animal models. This approach has the potential to produce more effective treatments by targeting critical elements of allergens, thus significantly advancing the understanding of allergy mechanisms and pathogenesis.
Mabylon’s future seems promising with the secured funding and strategic leadership changes. By concentrating on high-priority areas of allergy therapies and leveraging human-derived antibody technology, the company is well-placed to address unmet medical needs. Potential breakthroughs in this research could lead to new standards in preventative allergy treatments if successful clinical trials result in viable therapeutic applications.
